# US 2024/0197669 A1 · Treatment of herpes zoster with topical tetracaine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197669 A1
- Document ID: US20240197669A1
- Status: Published application
- Kind: A1
- Application number: 18/068,403
- Filed: 2022-12-19
- Published: 2024-06-20
- Earliest claimed: 2022-12-19
- Assignees: Pagari Life Science Corp
- Applicants: Pagari Life Science Corp
- Inventors: Alan J. Wickenhauser; Stephen E. Peipert
- Web page: https://patentgrep.com/patent/US20240197669A1

## CPC

- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 31/22: for herpes viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of treating herpes zoster (shingles), such as in the acute eruptive phase, comprising topically administering tetracaine base (or a pharmaceutically acceptable salt thereof) to a patient in need of such treatment.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

A method of treating herpes zoster in the active eruptive phase in a patient in need thereof comprising topically administering to the patient a composition comprising from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, based on the 100% total weight of the composition.

### Claim 4

A method of treating lesions associated with herpes zoster in the active eruptive phase in a patient in need thereof comprising topically administering to the patient a composition comprising (i) from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, based on the 100% total weight of the composition, wherein an effective amount of the composition is administered to treat the lesions associated with herpes zoster in the active eruptive phase.

### Claim 5

A method of treating one or more symptoms associated with herpes zoster in the active eruptive phase in a patient in need thereof comprising topically administering to the patient a composition comprising (i) from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, based on the 100% total weight of the composition, wherein an effective amount of the composition is administered to treat the one or more symptoms associated with herpes zoster in the active eruptive phase.

### Claim 6 (depends on 5)

The method of claim 5, wherein the one or more symptoms are selected from lesions, blisters, rash, mild to severe pain, pruritus, hyperesthesia, and any combination of any of the foregoing.

### Claim 7 (depends on 3)

The method of claim 3, wherein the composition comprises from about 2 wt. % to about 10 wt. % of tetracaine base.

### Claim 8 (depends on 3)

The method of claim 3, wherein the composition comprises from about 2 wt. % to about 10 wt. % of tetracaine hydrochloride.

### Claim 9 (depends on 3)

The method of claim 3, wherein the composition comprises a carrier comprising a non-aqueous vehicle.

### Claim 10

A method of treating herpes zoster in the active eruptive phase in a patient in need thereof comprising topically administering to the patient a composition comprising from about 2 wt. % to about 10 wt. % of tetracaine base or a pharmaceutically acceptable salt thereof, based on the 100% total weight of the composition, wherein the composition comprises a carrier comprising a non-aqueous vehicle, and the non-aqueous vehicle comprises a high molecular weight poly(ethylene oxide) homopolymer, a cellulose polymer, propylene glycol and a plasticized hydrocarbon gel.

### Claim 11 (depends on 1)

The method of claim 1, wherein the poly(ethylene oxide) homopolymer has a molecular weight of about 4,000,000 daltons.

### Claim 12 (depends on 10)

The method of claim 10, wherein the poly(ethylene oxide) is present in an amount of about 5 wt. % and the cellulose polymer is sodium carboxymethylcellulose and is present in an amount of about 4 wt. %.

### Claim 13 (depends on 10)

The method of claim 10, wherein the propylene glycol is present in an amount of about 5 wt. % to about 15 wt. %.

### Claim 14 (depends on 3)

The method of claim 3, wherein the composition comprises about 2 wt. % of tetracaine base.

### Claim 15 (depends on 3)

The method of claim 3, wherein the composition comprises about 6 wt. % of tetracaine base.

### Claim 16 (depends on 3)

The method of claim 3, wherein the composition is topically applied up to three times a day.

### Claim 17 (depends on 3)

The method of claim 3, wherein tetracaine base is the sole active ingredient in the composition.

### Claim 18 (depends on 4)

The method of claim 4, wherein the composition comprises from about 2 wt. % to about 10 wt. % of tetracaine base.

### Claim 19 (depends on 4)

The method of claim 4, wherein the composition comprises a carrier comprising a non-aqueous vehicle.

### Claim 20 (depends on 19)

The method of claim 19, wherein the non-aqueous vehicle comprises a high molecular weight poly(ethylene oxide) homopolymer, a cellulose polymer, propylene glycol and a plasticized hydrocarbon gel.

### Claim 21 (depends on 20)

The method of claim 20, wherein the poly(ethylene oxide) homopolymer has a molecular weight of about 4,000,000 daltons.

### Claim 22 (depends on 20)

The method of claim 20, wherein the poly(ethylene oxide) is present in an amount of about 5 wt. % and the cellulose polymer is sodium carboxymethylcellulose and is present in an amount of about 4 wt. %.

### Claim 23 (depends on 20)

The method of claim 20, wherein the propylene glycol is present in an amount of about 5 wt. % to about 15 wt. %.

### Claim 24 (depends on 4)

The method of claim 4, wherein the composition comprises about 6 wt. % of tetracaine base.

### Claim 25 (depends on 4)

The method of claim 4, wherein the composition is topically applied up to three times a day.

### Claim 26 (depends on 4)

The method of claim 4, wherein tetracaine base is the sole active ingredient in the composition.
